Oxford, UK – 15 December 2016. OGT, The Molecular Genetics Company, has expanded its range of CytoCell Aquarius® fluorescence in situ hybridization (FISH) probes for pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available, facilitating cancer research and diagnosis.
Developed in response to customer need, the genes for both FUS and FOXO1 are both implicated in several debilitating neoplastic diseases. Recurrent rearrangements involving the FUS gene with a number of different partner genes have been reported in various types of neoplastic disease, notably soft tissue sarcomas and acute myeloid leukemia. Translocations involving the FOXO1 gene are associated with around 80% of cases of alveolar rhabdomyosarcoma.
Commenting on the latest launch of Aquarius FISH probes, Steve Chatters, Senior Product Manager for Pathology at OGT, explained: “These new probes clearly show OGT’s commitment to being a market leader for high-quality FISH probes in the fast-moving field of cancer research; with over 20 new FISH probes released in the last year, CytoCell’s FISH portfolio is second-to-none in both range and quality. We are committed to keeping up with our customers’ expectations by further expanding the CytoCell cancer FISH probe range in 2017.”
Thanks to their excellent specificity, CytoCell Aquarius FISH probes deliver high-intensity signals with minimal background fluorescence. Probes are supplied as ready-to-use, premixed solutions to minimize the risks of experimental errors, delivering confidence in results.
Within the CytoCell portfolio, FUS Proximal Probe Red, FUS Distal Probe Green, FOXO1 Proximal Probe Green, FOXO1 Distal Probe Red, TFE3 Proximal Probe Red and TFE3 Distal Probe Green have been released as Analyte Specific Reagents (ASRs) in the United States.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.